Other monoclonal antibodies of EGFR are still under intensive investigation, including panitumumab, nimotuzumab, zalutumumab, etc. Similar to cetuximab, panitumumab cannot replace cisplatin when combined with radiotherapy for LA-HNSCC according to the results from the CONCERT-2401 and HN.6402 trials. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.